High-Density Lipoprotein-like Magnetic Nanostructures (HDL-MNS): Theranostic Agents for Cardiovascular Disease

Nandwana, Vikas; Ryoo, Soo‐Ryoon; Kanthala, Shanthi; McMahon, Kaylin M.; Rink, Jonathan S.; Li, Yue; Venkatraman, Subbu; Thaxton, C. Shad; Dravid, Vinayak P.

doi:10.1021/acs.chemmater.6b05357

Cited by 42 publications

(41 citation statements)

References 41 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Magnetic nanoparticles (MNPs) display physical and chemical properties different those found in their corresponding bulk materials. These properties make them attractive in widespread applications such as energy, electronics, sensor designs of all kinds, catalysts, magnetic refrigeration, optics, and in various biomedical applications [1][2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and ESR Study of Transition from Ferromagnetism to Superparamagnetism in La_0.8Sr_0.2MnO₃ Nanomanganite

Yahya¹,

Hosni²,

Hamzaoui³

2020

Smart Nanosystems for Biomedicine, Optoelectronics and Catalysis

View full text Add to dashboard Cite

Electron spin resonance (ESR) spectroscopy was used to determine the magnetic state transitions of nanocrystalline La 0.8 Sr 0.2 MnO 3 at room temperature, as a function of crystallite size. Ferromagnetic nanoparticles having an average crystallite size ranging from 9 to 57 nm are prepared by adopting the autocombustion method with two-step synthesis process. Significant changes of the ESR spectra parameters, such as the line shape, resonance field (Hr), g-factor, linewidth (∆Hpp), and the low-field microwave absorption (LFMA) signal, are indicative of the change in magnetic domain structures from superparamagnetism to single-domain and multi-domain ferromagnetism by increase in the crystallite size. Samples with crystallite sizes less than 24.5 nm are in a superparamagnetic state. Between 24.5 and 32 nm, they are formed by a single-domain ferromagnetic. The multi-domain state arises for higher sizes. In superparamagnetic region, the value of g-factor is practically constant suggesting that the magnetic core size is invariant with decreasing crystallite size. This contradictory observation with the core-shell model was explained by the phenomenon of phase separation that leads to the formation of a new magnetic state that we called multicore superparamagnetic state.

show abstract

Section: Introductionmentioning

confidence: 99%

Synthesis and ESR Study of Transition from Ferromagnetism to Superparamagnetism in La_0.8Sr_0.2MnO₃ Nanomanganite

Yahya¹,

Hosni²,

Hamzaoui³

2020

Smart Nanosystems for Biomedicine, Optoelectronics and Catalysis

View full text Add to dashboard Cite

show abstract

“…The respective cholesterol efflux percentage of HDL-MNS A was 4.8%, which was better than HDL-MNS B (2.4%) and apoA-I alone (3.2%), and similar to that of native HDL (4.7%) ( Fig. 5f ) [64].…”

Section: Hdl Mimicking Nps As Theranostic Agentsmentioning

confidence: 79%

High density lipoprotein mimicking nanoparticles for atherosclerosis

et al. 2020

View full text Add to dashboard Cite

Atherosclerosis is a major contributor to many cardiovascular events, including myocardial infarction, ischemic stroke, and peripheral arterial disease, making it the leading cause of death worldwide. High-density lipoproteins (HDL), also known as "good cholesterol", have been shown to demonstrate anti-atherosclerotic efficacy through the removal of cholesterol from foam cells in atherosclerotic plaques. Because of the excellent anti-atherosclerotic properties of HDL, in the past several years, there has been tremendous attention in designing HDL mimicking nanoparticles (NPs) of varying functions to image, target, and treat atherosclerosis. In this review, we are summarizing the recent progress in the development of HDL mimicking NPs and their applications for atherosclerosis.

show abstract

“…High‐density lipoprotein‐like magnetic nanostructures (HDL‐MNS) have been studied for their imaging (via MRI) and therapeutic effects (reverse cholesterol transport) on macrophage‐rich and cholesterol‐rich atherosclerotic lesions. Non‐invasive synergistic therapeutic effects may be achieved with this kind of nanomaterial upon loading with other anti‐inflammatory drugs . Bagalkot et al .…”

Section: Theranostic Nanomedicine For Atherosclerosismentioning

confidence: 99%

Treatment of atherosclerotic plaque: perspectives on theranostics

Zhang

Koradia

Kamato

et al. 2019

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives Atherosclerosis, a progressive condition characterised by the build-up of plaque due to the accumulation of low-density lipoprotein and fibrous substances in the damaged arteries, is the major underlying pathology of most cardiovascular diseases. Despite the evidence of the efficacy of the present treatments for atherosclerosis, the complex and poorly understood underlying mechanisms of atherosclerosis development and progression have prevented them from reaching their full potential. Novel alternative treatments like usage of nanomedicines and theranostics are gaining attention of the researchers worldwide. This review will briefly discuss the current medications for the disease and explore potential future developments based on theranostics nanomaterials that may help resolve atherosclerotic cardiovascular disease. Key findings Various drugs can slow the effects of atherosclerosis. They include hyperlipidaemia medications, anti-platelet drugs, hypertension and hyperglycaemia medications. Most of the theranostic agents developed for atherosclerosis have shown the feasibility of rapid and noninvasive diagnosis, as well as effective and specific treatment in animal models. However, there are still some limitation exist in their structure design, stability, targeting efficacy, toxicity and production, which should be optimized in order to develop clinically acceptable nanoparticle based theronostics for atherosclerosis. Summary Current medications for atherosclerosis and potential theranostic nanomaterials developed for the disease are discussed in the current review. Further investigations remain to be carried out to achieve clinical translation of theranostic agents for atherosclerosis.

show abstract

High-Density Lipoprotein-like Magnetic Nanostructures (HDL-MNS): Theranostic Agents for Cardiovascular Disease

Cited by 42 publications

References 41 publications

Synthesis and ESR Study of Transition from Ferromagnetism to Superparamagnetism in La_0.8Sr_0.2MnO₃ Nanomanganite

Synthesis and ESR Study of Transition from Ferromagnetism to Superparamagnetism in La_0.8Sr_0.2MnO₃ Nanomanganite

High density lipoprotein mimicking nanoparticles for atherosclerosis

Treatment of atherosclerotic plaque: perspectives on theranostics

Contact Info

Product

Resources

About

High-Density Lipoprotein-like Magnetic Nanostructures (HDL-MNS): Theranostic Agents for Cardiovascular Disease

Cited by 42 publications

References 41 publications

Synthesis and ESR Study of Transition from Ferromagnetism to Superparamagnetism in La0.8Sr0.2MnO3 Nanomanganite

Synthesis and ESR Study of Transition from Ferromagnetism to Superparamagnetism in La0.8Sr0.2MnO3 Nanomanganite

High density lipoprotein mimicking nanoparticles for atherosclerosis

Treatment of atherosclerotic plaque: perspectives on theranostics

Contact Info

Product

Resources

About

Synthesis and ESR Study of Transition from Ferromagnetism to Superparamagnetism in La_0.8Sr_0.2MnO₃ Nanomanganite

Synthesis and ESR Study of Transition from Ferromagnetism to Superparamagnetism in La_0.8Sr_0.2MnO₃ Nanomanganite